Login
$ELVN
$47.62 -$1.18 (2.42%) Live

$ELVN SEC Filings

Filed On Filing
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial

03 Nov 2026 Form 4: Kunkel Lori Anne, Director

Received 11,041 shares by exercise or conversion ($138K)

27 Oct 2026 SCHEDULE 13G/A
21 Oct 2026 Form 4: Hohl Benjamin, CHIEF FINANCIAL OFFICER

Received 6,018 shares by exercise or conversion ($89.4K) · Sold 6,018 shares ($232K)

21 Oct 2026 Form 4: Collins Helen Louise, CHIEF MEDICAL OFFICER

Received 5,000 shares by exercise or conversion ($12.4K) · Sold 5,000 shares ($192K)

19 Oct 2026 144
16 Oct 2026 Form 4: Ball Kristine M, Director

Granted 23,394 Stock Option (right to buy)

16 Oct 2026 Form 3: Ball Kristine M, Director

No securities owned

14 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness

05 Oct 2026 Form 4: Garland J. Scott, Director

Received 13,000 shares by exercise or conversion ($201K) · Sold 13,000 shares ($607K)

01 Oct 2026 144
21 Sep 2026 Form 4: Hohl Benjamin, CHIEF FINANCIAL OFFICER

Received 3,982 shares by exercise or conversion ($59.1K) · Sold 6,018 shares ($303K)

21 Sep 2026 Form 4: Collins Helen Louise, CHIEF MEDICAL OFFICER

Received 5,000 shares by exercise or conversion ($12.4K) · Sold 5,000 shares ($252K)

17 Sep 2026 144
04 Sep 2026 144
19 Aug 2026 Form 4: Hohl Benjamin, CHIEF FINANCIAL OFFICER

Sold 6,018 shares ($353K)

19 Aug 2026 Form 4: Collins Helen Louise, CHIEF MEDICAL OFFICER

Received 5,000 shares by exercise or conversion ($12.4K) · Sold 5,000 shares ($293K)

06 Aug 2026 Form 4: Derynck Mika K, Director

Received 158,795 shares by exercise or conversion ($1.72M) · Sold 158,795 shares ($9.56M)

06 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support